← All trials
NCT05942547
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2023
- Primary completion
- Oct 10, 2023
- Completion date
- Jun 10, 2025
- First posted
- Jul 12, 2023
- Last posted
- Jul 12, 2023
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tanta UniversityLead sponsor
- Tanta UniversityOverall official - principal investigator
- Tanta UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.